Optimi Health files a provisional patent application for a stable extraction method for natural psilocybin.
Optimi Health files a provisional patent application for a stable extraction method for natural psilocybin.
Mydecine's lead drug candidate, MYCO-001 will be used in a major, new smoking cessation clinical study by Johns Hopkins.
The Schedule I classification for psychedelic drugs needs to be changed. But to what -- and when? Psychedelic Stock Watch takes a broad look at that question.
Mydecine spins out the company's cannabis assets into a private subsidiary, to comply with with the regulatory requirements of both the NASDAQ and London Stock Exchange.
MINDCURE announces its addition to the OTCQX Best Markets tier.
Novamind opens the 6th mental health clinic in its Cedar Psychiatry network, located in Murray, Utah. Novamind is now projecting a total of 65,000 clinic visits this year.
Two billion people suffer from treatable mental health disorders resulting in 8 million preventable deaths per year. Psychedelics can address this catastrophe -- but first these drugs must be legalized.
Private company Delix Therapeutics raises $70 million, focusing on non-hallucinatory candidates to treat brain disorders.
MINDCURE launches "Desire Project", taking a psychotherapy approach to female hypocactive sexual disorder.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now